Educational Strategy on a Vulnerable Population to Improve Cardiovascular Health and Food Insecurity

Launched by MAIMÓNIDES BIOMEDICAL RESEARCH INSTITUTE OF CÓRDOBA · May 13, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on improving heart health and addressing food insecurity through an educational program designed to teach participants about healthy lifestyle choices. The goal is to help people better understand how to take care of their health, which could lead to longer-term improvements in their well-being and reduce issues related to not having enough healthy food.

To participate in this study, individuals should be between the ages of 12 and 79 and generally healthy, meaning they do not have serious diseases that would limit their life expectancy. Participants will need to give informed consent, which means they agree to take part in the study after understanding what it involves. Throughout the trial, participants will learn about making healthier choices and may discover new ways to improve their overall health. It’s important to note that those with existing heart conditions or serious health issues, as well as pregnant or breastfeeding women, are not eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants from the general population without disabling diseases or whose severity implies a life expectancy of less than five years
• • Informed Consent
• Exclusion Criteria:
• • Age less than 12 years or equal to or greater than 80 years, with a life expectancy, not less than 5 years.
• • Patients with established cardiovascular disease
• • Patients with limitations to follow the protocol
• • Serious or difficult-to-control risk factors: Patients with hypertension and diabetes with organic involvement that limits their survival and disabling clinical manifestations of cerebral arteriosclerosis will be excluded.
• • Chronic diseases not related to coronary risk: severe psychiatric diseases, chronic processes requiring treatment such as chronic renal failure, chronic liver disease, neoplasms undergoing treatment, severe and very severe chronic obstructive pulmonary disease, endocrinopathies susceptible to decompensation, and digestive tract diseases.
• • Participants in other clinical trials at screening or within 30 days prior to start.
• • Excessive alcohol and drug abuse
• • Pregnant or lactating women.